


The listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Currently Amended) A compound of formula I



in which

R1 is hydrogen, 1-4C-alkyl, halogen, or 1-4C-alkoxy,

R2 is hydrogen or 1-4C-alkyl,

R3 is hydrogen or 1-4C-alkyl,

R4 is hydrogen, 1-4C-alkyl, halogen, or 1-4C-alkoxy,

R5 is hydrogen, 1-4C-alkyl, halogen, or 1-4C-alkoxy,

R6 is -T1-Q1, in which

T1 is a bond, or 1-4C-alkylene,

Q1 is Ar1, in which

Ar1 is phenyl, or R61- and/or R62-substituted phenyl, in which

R61 is 1-4C-alkyl, or -T2-N(R611)R612, in which

either

T2 is a bond, and

R611 is hydrogen, 1-4C-alkyl, hydroxy-2-4C-alkyl, 1-4C-alkoxy-2-4C-alkyl, phenyl-1-4C-alkyl, or Har1-1-4C-alkyl, in which

Har1 is optionally substituted by R6111 and/or R6112, and is a monocyclic or fused bicyclic 5- to 10-membered unsaturated heteroaromatic ring comprising one to three heteroatoms, each of which is selected from the group consisting of nitrogen, oxygen and sulfur, in which

R6111 is halogen, or 1-4C-alkyl,

R6112 is 1-4C-alkyl, and

R612 is hydrogen, 1-4C-alkyl, 1-4C-alkoxy-2-4C-alkyl or hydroxy-2-4C-alkyl,

or R611 and R612 together and with inclusion of the nitrogen atom, to which they are bonded, form a heterocyclic ring Het1, in which

Het1 is morpholino, thiomorpholino, S-oxo-thiomorpholino, S,S-dioxo-thiomorpholino, piperidino, pyrrolidino, piperazino, or 4N-(1-4C-alkyl)-piperazino,

or

T2 is 1-4C-alkylene, or 2-4C-alkylene interrupted by oxygen, and

R611 is hydrogen, 1-4C-alkyl, hydroxy-2-4C-alkyl, 1-4C-alkoxy-2-4C-alkyl, phenyl-1-4C-alkyl, or Har1-1-4C-alkyl, in which

Har1 is optionally substituted by R6111 and/or R6112, and is a monocyclic or fused bicyclic 5- to 10-membered unsaturated heteroaromatic ring comprising one to three heteroatoms, each of which is selected from the group consisting of nitrogen, oxygen and sulfur, in which

R6111 is halogen, or 1-4C-alkyl,

R6112 is 1-4C-alkyl, and

R612 is hydrogen, 1-4C-alkyl, 1-4C-alkoxy-2-4C-alkyl or hydroxy-2-4C-alkyl,


or R611 and R612 together and with inclusion of the nitrogen atom, to which they are bonded, form a heterocyclic ring Het1, in which

Het1 is morpholino, thiomorpholino, S-oxo-thiomorpholino, S,S-dioxo-thiomorpholino, piperidino, pyrrolidino, piperazino, 4N-(1-4C-alkyl)-piperazino, imidazolo, pyrrolo or pyrazolo,

R62 is 1-4C-alkyl, 1-4C-alkoxy, halogen, cyano, 1-4C-alkoxy-1-4C-alkyl, 1-4C-alkylcarbonylamino, or 1-4C-alkylsulphonylamino,

R7 is hydroxyl, or Cyc1, in which

Cyc1 is a ring system of formula Ia



in which

A is C (carbon),

B is C (carbon),

R71 is hydrogen, halogen, 1-4C-alkyl, or 1-4C-alkoxy,

R72 is hydrogen, halogen, 1-4C-alkyl, or 1-4C-alkoxy,

M with inclusion of A and B is either a ring Ar2 or a ring Har2, in which

Ar2 is a benzene ring,


Har2 is a monocyclic 5- or 6-membered unsaturated heteroaromatic ring comprising one to three heteroatoms, each of which is selected from the group consisting of nitrogen, oxygen and sulfur,

or a salt thereof.

2. (Previously Presented) A compound of formula I according to claim 1

in which

- R1 is hydrogen, 1-4C-alkyl, halogen, or 1-4C-alkoxy,  
R2 is hydrogen or 1-4C-alkyl,  
R3 is hydrogen or 1-4C-alkyl,  
R4 is hydrogen, 1-4C-alkyl, halogen, or 1-4C-alkoxy,  
R5 is hydrogen, 1-4C-alkyl, halogen, or 1-4C-alkoxy,  
R6 is -T1-Q1, in which  
T1 is a bond, or 1-4C-alkylene,  
Q1 is Ar1, in which  
Ar1 is phenyl, or R61- and/or R62-substituted phenyl, in which  
R61 is 1-4C-alkyl, or -T2-N(R611)R612, in which  
T2 is a bond, 1-4C-alkylene, or 2-4C-alkylene interrupted by oxygen,  
R611 is hydrogen, 1-4C-alkyl, hydroxy-2-4C-alkyl, 1-4C-alkoxy-2-4C-alkyl, phenyl-1-4C-alkyl, or Har1-1-4C-alkyl, in which  
Har1 is optionally substituted by R6111 and/or R6112, and is a monocyclic or fused bicyclic 5- to 10-membered unsaturated heteroaromatic ring comprising one to three heteroatoms, each of which is selected from the group consisting of nitrogen, oxygen and sulfur, in which  
R6111 is halogen, or 1-4C-alkyl,  
R6112 is 1-4C-alkyl,  
R612 is hydrogen, 1-4C-alkyl, 1-4C-alkoxy-2-4C-alkyl or hydroxy-2-4C-alkyl,  
R62 is 1-4C-alkyl, 1-4C-alkoxy, halogen, cyano, 1-4C-alkoxy-1-4C-alkyl, 1-4C-alkylcarbonylamino, or 1-4C-alkylsulphonylamino,  
R7 is hydroxyl, or Cyc1, in which  
Cyc1 is a ring system of formula Ia



in which

- A is C (carbon),  
B is C (carbon),  
R71 is hydrogen, halogen, 1-4C-alkyl, or 1-4C-alkoxy,  
R72 is hydrogen, halogen, 1-4C-alkyl, or 1-4C-alkoxy,  
M with inclusion of A and B is either a ring Ar2 or a ring Har2, in which  
Ar2 is a benzene ring,  
Har2 is a monocyclic 5- or 6-membered unsaturated heteroaromatic ring comprising one to three heteroatoms, each of which is selected from the group consisting of nitrogen, oxygen and sulfur,

or a salt thereof.

3. (Currently Amended) A compound of formula I according to claim 1  
in which

R1 is hydrogen, or 1-4C-alkyl,

R2 is hydrogen, or 1-4C-alkyl,

R3 is hydrogen, or 1-4C-alkyl,

R4 is hydrogen, or 1-4C-alkyl,

R5 is hydrogen, or 1-4C-alkyl,

R6 is -T1-Q1, in which

T1 is a bond, or 1-4C-alkylene,

Q1 is Ar1, in which

Ar1 is phenyl, or R61-substituted phenyl, in which

R61 is 1-4C-alkyl, or -T2-N(R611)R612, in which

either

T2 is a bond,

R611 is hydrogen, 1-4C-alkyl, phenyl-1-4C-alkyl, or Har1-1-4C-alkyl, in which

Har1 is either

a monocyclic 5-membered unsaturated heteroaromatic ring comprising one, two or three heteroatoms, each of which is selected from the group consisting of nitrogen, oxygen and sulfur, or

a monocyclic 6-membered unsaturated heteroaromatic ring comprising one or two nitrogen atoms, or

a fused bicyclic 9-membered unsaturated heteroaromatic ring comprising one, two or three heteroatoms, each of which is selected from the group consisting of nitrogen, oxygen and sulfur, or

a fused bicyclic 10-membered unsaturated heteroaromatic ring comprising one or two heteroatoms, each of which is selected from the group consisting of nitrogen, oxygen and sulfur, and

R612 is hydrogen, 1-4C-alkyl, or hydroxy-2-4C-alkyl,

~~or R611 and R612 together and with inclusion of the nitrogen atom, to which they are bonded, form a heterocyclic ring Het1, in which~~

~~Het1 is morpholine,~~

~~or~~

~~T2 is 1-4C-alkylene,~~

~~R611 is hydrogen, 1-4C-alkyl, phenyl-1-4C-alkyl, or Har1-1-4C-alkyl, in which~~

~~Har1 is either~~

a monocyclic 5-membered unsaturated heteroaromatic ring comprising one, two or three heteroatoms, each of which is selected from the group consisting of nitrogen, oxygen and sulfur, or  
 a monocyclic 6-membered unsaturated heteroaromatic ring comprising one or two nitrogen atoms, or  
 a fused bicyclic 9-membered unsaturated heteroaromatic ring comprising one, two or three heteroatoms, each of which is selected from the group consisting of nitrogen, oxygen and sulfur, or  
 a fused bicyclic 10-membered unsaturated heteroaromatic ring comprising one or two heteroatoms, each of which is selected from the group consisting of nitrogen, oxygen and sulfur, and

R612 is hydrogen, 1-4C-alkyl, or hydroxy-2-4C-alkyl,  
 or R611 and R612 together and with inclusion of the nitrogen atom, to which they are bonded, form a heterocyclic ring Het1, in which  
 Het1 is morpholino,  
 R7 is hydroxyl, or 2-aminophenyl,  
 or a salt thereof.

4. (Currently Amended) A compound of formula I according to claim 1  
 in which

R1 is hydrogen,  
 R2 is hydrogen,  
 R3 is hydrogen,  
 R4 is hydrogen,  
 R5 is hydrogen,  
 R6 is -T1-Q1, in which  
 T1 is a bond, or 1-2C-alkylene,  
 Q1 is Ar1, in which  
 Ar1 is phenyl, or R61-substituted phenyl, in which  
 R61 is 1-4C-alkyl, or -T2-N(R611)R612, in which

either

T2 is a bond,  
 R611 is hydrogen, 1-4C-alkyl, phenyl-1-2C-alkyl, or Har1-1-2C-alkyl, in which  
 Har1 is pyridinyl, benzimidazolyl, benzoxazolyl, benzofuranyl, benzothiophenyl or indolyl, and  
 R612 is hydrogen, 1-4C-alkyl, or hydroxy-2-3C-alkyl,

~~or R611 and R612 together and with inclusion of the nitrogen atom, to which they are bonded, form a heterocyclic ring Het1, in which~~

~~Het1 is morpholino,~~

or

T2 is 1-2C-alkylene,  
 R611 is hydrogen, 1-4C-alkyl, phenyl-1-2C-alkyl, or Har1-1-2C-alkyl, in which  
 Har1 is pyridinyl, benzimidazolyl, benzoxazolyl, benzofuranyl, benzothiophenyl or indolyl, and  
 R612 is hydrogen, 1-4C-alkyl, or hydroxy-2-3C-alkyl,  
 or R611 and R612 together and with inclusion of the nitrogen atom, to which they are bonded, form a  
 heterocyclic ring Het1, in which  
 Het1 is morpholino,  
 R7 is hydroxyl, or 2-aminophenyl,  
 or a salt thereof.

5. (Previously Presented) A compound of formula I according to claim 1  
 in which

R1 is hydrogen,  
 R2 is hydrogen,  
 R3 is hydrogen,  
 R4 is hydrogen,  
 R5 is hydrogen,  
 R6 is -T1-Q1, or benzyl, in which  
 T1 is a bond,  
 Q1 is Ar1, in which  
 Ar1 is phenyl, or R61-substituted phenyl, in which  
 R61 is 1-4C-alkyl, or -T2-N(R611)R612, in which  
 either

T2 is a bond,  
 R611 is 1-4C-alkyl, and  
 R612 is 1-4C-alkyl,  
 or

T2 is 1-2C-alkylene,  
 R611 is hydrogen, 1-4C-alkyl, phenyl-1-2C-alkyl, or Har1-1-2C-alkyl, in which  
 Har1 is pyridinyl, or indolyl, and  
 R612 is hydrogen, 1-4C-alkyl, or hydroxy-2-3C-alkyl,  
 or R611 and R612 together and with inclusion of the nitrogen atom, to which they are bonded, form a  
 heterocyclic ring Het1, in which  
 Het1 is morpholino,  
 R7 is hydroxyl, or 2-aminophenyl,  
 or a salt thereof.

6. (Previously Presented) A compound of formula I according to claim 1  
 in which

R1 is hydrogen,  
 R2 is hydrogen,  
 R3 is hydrogen,  
 R4 is hydrogen,  
 R5 is hydrogen,  
 R6 is -T1-Q1, or benzyl, in which  
 T1 is a bond,  
 Q1 is Ar1, in which  
 Ar1 is phenyl, 3-(R61)-phenyl, or 4-(R61)-phenyl, in which  
 R61 is methyl, or -T2-N(R611)R612, in which  
 either  
 T2 is a bond,  
 R611 is methyl, and  
 R612 is methyl,  
 or  
 T2 is methylene,  
 R611 is hydrogen, methyl, isobutyl, benzyl, Har1-methyl, or 2-(Har1)-ethyl in which  
 Har1 is pyridinyl or indolyl, and  
 R612 is hydrogen, methyl, or 2-hydroxy-ethyl,  
 or R611 and R612 together and with inclusion of the nitrogen atom, to which they are bonded, form a  
 heterocyclic ring Het1, in which  
 Het1 is morpholino,  
 R7 is hydroxyl, or 2-aminophenyl,  
 or a salt thereof.

**7.** (Previously Presented) A compound of formula I according to claim 1  
 in which

R1 is hydrogen,  
 R2 is hydrogen,  
 R3 is hydrogen,  
 R4 is hydrogen,  
 R5 is hydrogen,  
 R6 is -T1-Q1, or benzyl, in which  
 T1 is a bond,  
 Q1 is Ar1, in which  
 Ar1 is phenyl, 3-(R61)-phenyl, or 4-(R61)-phenyl, in which  
 R61 is methyl, or -T2-N(R611)R612, in which  
 either  
 T2 is a bond,

R611 is methyl, and  
 R612 is methyl,  
 or  
 T2 is methylene,  
 R611 is hydrogen, methyl, isobutyl, benzyl, Har1-methyl, or 2-(Har1)-ethyl in which  
 Har1 is pyridin-3-yl, pyridin-4-yl, indol-2-yl, indol-3-yl or indol-5-yl, and  
 R612 is hydrogen, methyl, or 2-hydroxy-ethyl,  
 or R611 and R612 together and with inclusion of the nitrogen atom, to which they are bonded, form a  
 heterocyclic ring Het1, in which  
 Het1 is morpholino,  
 R7 is hydroxyl, or 2-aminophenyl,  
 or a salt thereof.

8. (Previously Presented) A compound of formula I according to claim 1  
 in which

R1 is hydrogen,  
 R2 is hydrogen,  
 R3 is hydrogen,  
 R4 is hydrogen,  
 R5 is hydrogen,  
 R6 is -T1-Q1, or benzyl, in which  
 T1 is a bond,  
 Q1 is Ar1, in which  
 Ar1 is phenyl, 3-(R61)-phenyl, or 4-(R61)-phenyl, in which  
 R61 is methyl, or -T2-N(R611)R612, in which  
 either  
 T2 is a bond,  
 R611 is methyl, and  
 R612 is methyl,  
 or  
 T2 is methylene,  
 R611 is hydrogen, isobutyl, benzyl, Har1-methyl, or 2-(Har1)-ethyl, in which  
 Har1 is pyridin-3-yl, pyridin-4-yl, indol-2-yl, indol-3-yl or indol-5-yl, and  
 R612 is hydrogen,  
 or  
 T2 is methylene,  
 R611 is methyl, or 2-(Har1)-ethyl, in which  
 Har1 is indol-2-yl, and  
 R612 is methyl,



or

T2 is methylene,  
R611 is 2-(Har1)-ethyl, in which  
Har1 is indol-2-yl, and  
R612 is 2-hydroxy-ethyl,

or

T2 is methylene, and  
R611 and R612 together and with inclusion of the nitrogen atom, to which they are bonded, form a  
heterocyclic ring Het1, in which  
Het1 is morpholino,

R7 is hydroxyl,  
or a salt thereof.

**9.** (Previously Presented) A compound of formula I according to claim 1  
in which

R1 is hydrogen,  
R2 is hydrogen,  
R3 is hydrogen,  
R4 is hydrogen,  
R5 is hydrogen,  
R6 is -T1-Q1, or benzyl, in which  
T1 is a bond,  
Q1 is Ar1, in which  
Ar1 is phenyl, 3-(R61)-phenyl, or 4-(R61)-phenyl, in which  
R61 is methyl, or -T2-N(R611)R612, in which

either

T2 is a bond,  
R611 is methyl, and  
R612 is methyl,

or

T2 is methylene,  
R611 is hydrogen, isobutyl, benzyl, Har1-methyl, or 2-(Har1)-ethyl, in which  
Har1 is pyridin-3-yl, pyridin-4-yl, indol-3-yl, or indol-5-yl, and  
R612 is hydrogen,

or

T2 is methylene,  
R611 is methyl, or 2-(Har1)-ethyl, in which  
Har1 is indol-2-yl, and

R612 is methyl,  
 or  
 T2 is methylene,  
 R611 is 2-(Har1)-ethyl, in which  
 Har1 is indol-2-yl, and  
 R612 is 2-hydroxy-ethyl,  
 or  
 T2 is methylene, and  
 R611 and R612 together and with inclusion of the nitrogen atom, to which they are bonded, form a  
 heterocyclic ring Het1, in which  
 Het1 is morpholino,  
 R7 is 2-aminophenyl,  
 or a salt thereof.

**10.** (Previously Presented) A compound of formula I according to claim 1  
 in which

R1 is hydrogen,  
 R2 is hydrogen,  
 R3 is hydrogen,  
 R4 is hydrogen,  
 R5 is hydrogen,  
 R6 is -T1-Q1, in which  
 T1 is a bond, or 1-2C-alkylene,  
 Q1 is Ar1, in which  
 Ar1 is phenyl, or R61-substituted phenyl, in which  
 R61 is 1-4C-alkyl, or -T2-N(R611)R612, in which  
 T2 is a bond, or 1-2C-alkylene,  
 R611 is 1-4C-alkyl, or Har1-1-2C-alkyl, in which  
 Har1 is benzimidazolyl, or indolyl,  
 R612 is 1-4C-alkyl,  
 R7 is hydroxyl, or 2-aminophenyl,  
 or a salt thereof.

**11.** (Previously Presented) A compound of formula I according to claim 1  
 in which

R1 is hydrogen,  
 R2 is hydrogen,  
 R3 is hydrogen,  
 R4 is hydrogen,

R5 is hydrogen,  
 R6 is -T1-Q1, or benzyl, in which  
 T1 is a bond,  
 Q1 is Ar1, in which  
 Ar1 is R61-substituted phenyl, in which  
 R61 is methyl, dimethylamino, or -T2-N(R611)R612, in which  
 T2 is methylene,  
 R611 is methyl, or 2-(indol-2-yl)ethyl,  
 R612 is methyl,  
 R7 is hydroxyl, or 2-aminophenyl,  
 or a salt thereof.

**12.** (Previously Presented) A compound which is selected from the group consisting of  
 (E)-N-Hydroxy-3-[1-(toluene-4-sulfonyl)-1H-pyrrol-3-yl]-acrylamide,  
 N-Hydroxy-3-(1-phenylmethanesulfonyl-1H-pyrrol-3-yl)-acrylamide,  
 (E)-3-[1-(4-Dimethylamino-benzenesulfonyl)-1H-pyrrol-3-yl]-N-hydroxy-acrylamide,  
 (E)-N-(2-Amino-phenyl)-3-[1-(toluene-4-sulfonyl)-1H-pyrrol-3-yl]-acrylamide,  
 (E)-N-(2-Amino-phenyl)-3-(1-phenylmethanesulfonyl-1H-pyrrol-3-yl)-acrylamide,  
 (E)-N-(2-Amino-phenyl)-3-[1-(4-dimethylamino-benzenesulfonyl)-1H-pyrrol-3-yl]-acrylamide,  
 (E)-N-Hydroxy-3-(1-[4-((2-(1H-indol-2-yl)-ethyl)-methyl-amino)-methyl]-benzene sulfonyl]-1H-pyrrol-3-yl)-acrylamide,  
 (E)-3-[1-(4-Dimethylaminomethyl-benzenesulfonyl)-1H-pyrrol-3-yl]-N-hydroxy-acrylamide,  
 (E)-N-Hydroxy-3-[1-(4-(((pyridin-3-ylmethyl)-amino)-methyl)-benzenesulfonyl)-1H-pyrrol-3-yl]-acrylamide,  
 (E)-N-Hydroxy-3-[1-(4-(((1H-indol-3-ylmethyl)-amino)-methyl)-benzenesulfonyl)-1H-pyrrol-3-yl]-acrylamide,  
 (E)-3-[1-(4-(Benzylamino-methyl)-benzenesulfonyl)-1H-pyrrol-3-yl]-N-hydroxy-acrylamide,  
 (E)-N-Hydroxy-3-[1-(4-(isobutylamino-methyl)-benzenesulfonyl)-1H-pyrrol-3-yl]-acrylamide,  
 (E)-N-Hydroxy-3-[1-(4-(((1H-indol-5-ylmethyl)-amino)-methyl)-benzenesulfonyl)-1H-pyrrol-3-yl]-acrylamide,  
 (E)-N-Hydroxy-3-[1-(4-(((pyridin-4-ylmethyl)-amino)-methyl)-benzenesulfonyl)-1H-pyrrol-3-yl]-acrylamide,  
 (E)-3-[1-(4-Aminomethyl-benzenesulfonyl)-1H-pyrrol-3-yl]-N-hydroxy-acrylamide,  
 (E)-N-Hydroxy-3-[1-(4-morpholin-4-ylmethyl-benzenesulfonyl)-1H-pyrrol-3-yl]-acrylamide,  
 (E)-N-Hydroxy-3-[1-(4-(((2-hydroxy-ethyl)-[2-(1H-indol-2-yl)-ethyl]-amino)-methyl)-benzenesulfonyl)-1H-pyrrol-3-yl]-acrylamide,  
 and the salts thereof.

**13.** (Cancelled)

**14.** (Previously Presented) A pharmaceutical composition comprising one or more compounds of formula I as claimed in claim 1, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable excipient and/or vehicle.

**15-25.** (Cancelled)

**26.** (Previously Presented) A compound according to claim 12, which is

(E)-N-Hydroxy-3-[1-(toluene-4-sulfonyl)-1H-pyrrol-3-yl]-acrylamide

N-Hydroxy-3-(1-phenylmethanesulfonyl-1H-pyrrol-3-yl)-acrylamide

(E)-3-[1-(4-Dimethylamino-benzenesulfonyl)-1H-pyrrol-3-yl]-N-hydroxy-acrylamide or

(E)-N-(2-Amino-phenyl)-3-[1-(4-dimethylamino-benzenesulfonyl)-1H-pyrrol-3-yl]-acrylamide  
or a salt thereof.

**27.** (Previously Presented) A compound according to claim 12, which is

(E)-N-Hydroxy-3-(1-[4-((2-(1H-indol-2-yl)-ethyl)-methyl-amino)-methyl]-benzene sulfonyl]-1H-pyrrol-3-yl)-acrylamide

(E)-3-[1-(4-Dimethylaminomethyl-benzenesulfonyl)-1H-pyrrol-3-yl]-N-hydroxy-acrylamide

(E)-N-Hydroxy-3-[1-(4-((pyridin-3-ylmethyl)-amino)-methyl)-benzenesulfonyl]-1H-pyrrol-3-yl]-acrylamide

(E)-N-Hydroxy-3-[1-(4-((1H-indol-3-ylmethyl)-amino)-methyl)-benzenesulfonyl]-1H-pyrrol-3-yl]-acrylamide

(E)-3-[1-(4-(Benzylamino-methyl)-benzenesulfonyl)-1H-pyrrol-3-yl]-N-hydroxy-acrylamide

(E)-N-Hydroxy-3-[1-(4-(isobutylamino-methyl)-benzenesulfonyl)-1H-pyrrol-3-yl]-acrylamide

(E)-N-Hydroxy-3-[1-(4-((1H-indol-5-ylmethyl)-amino)-methyl)-benzenesulfonyl]-1H-pyrrol-3-yl]-acrylamide

(E)-N-Hydroxy-3-[1-(4-((pyridin-4-ylmethyl)-amino)-methyl)-benzenesulfonyl]-1H-pyrrol-3-yl]-acrylamide

(E)-3-[1-(4-Aminomethyl-benzenesulfonyl)-1H-pyrrol-3-yl]-N-hydroxy-acrylamide

(E)-N-Hydroxy-3-[1-(4-morpholin-4-ylmethyl-benzenesulfonyl)-1H-pyrrol-3-yl]-acrylamide or

(E)-N-Hydroxy-3-[1-(4-((2-hydroxy-ethyl)-[2-(1H-indol-2-yl)-ethyl]-amino)-methyl)-benzenesulfonyl]-1H-pyrrol-3-yl]-acrylamide

or a salt thereof.